Strategic and Technical Considerations in Manufacturing Viral Vector Vaccines for the Biomedical Advanced Research and Development Authority Threats
Over the past few decades, the world has seen a considerable uptick in the number of new and emerging infectious disease outbreaks. The development of new vaccines, vaccine technologies, and platforms are critical to enhance our preparedness for biological threats and prevent future pandemics. Viral...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/1/73 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587374011351040 |
|---|---|
| author | Lindsay A. Parish Shyam Rele Kimberly A. Hofmeyer Brooke B. Luck Daniel N. Wolfe |
| author_facet | Lindsay A. Parish Shyam Rele Kimberly A. Hofmeyer Brooke B. Luck Daniel N. Wolfe |
| author_sort | Lindsay A. Parish |
| collection | DOAJ |
| description | Over the past few decades, the world has seen a considerable uptick in the number of new and emerging infectious disease outbreaks. The development of new vaccines, vaccine technologies, and platforms are critical to enhance our preparedness for biological threats and prevent future pandemics. Viral vectors can be an important tool in the repertoire of technologies available to develop effective vaccines against new and emerging infectious diseases. In many instances, vaccines may be needed in a reactive scenario, requiring technologies than can elicit rapid and robust immune responses with a single dose. Here, we discuss how viral vector vaccines are utilized in a vaccine portfolio for priority biological threats, some of the challenges in manufacturing viral vector vaccines, the need to strengthen live virus manufacturing capabilities, and future opportunities to capitalize on the use of viral vectors to improve the sustainability of the Biomedical Advanced Research and Development Authority’s vaccine portfolio. |
| format | Article |
| id | doaj-art-9c4f736466c94e2c85d677e30c3830ee |
| institution | Kabale University |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-9c4f736466c94e2c85d677e30c3830ee2025-01-24T13:51:51ZengMDPI AGVaccines2076-393X2025-01-011317310.3390/vaccines13010073Strategic and Technical Considerations in Manufacturing Viral Vector Vaccines for the Biomedical Advanced Research and Development Authority ThreatsLindsay A. Parish0Shyam Rele1Kimberly A. Hofmeyer2Brooke B. Luck3Daniel N. Wolfe4CBRN Vaccines, Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Washington, DC 20201, USADivision of Research, Innovation, and Ventures (DRIVe), Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Washington, DC 20201, USACBRN Vaccines, Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Washington, DC 20201, USAPharmaceutical Countermeasures Infrastructure (PCI) Division, Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Washington, DC 20201, USACBRN, Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Washington, DC 20201, USAOver the past few decades, the world has seen a considerable uptick in the number of new and emerging infectious disease outbreaks. The development of new vaccines, vaccine technologies, and platforms are critical to enhance our preparedness for biological threats and prevent future pandemics. Viral vectors can be an important tool in the repertoire of technologies available to develop effective vaccines against new and emerging infectious diseases. In many instances, vaccines may be needed in a reactive scenario, requiring technologies than can elicit rapid and robust immune responses with a single dose. Here, we discuss how viral vector vaccines are utilized in a vaccine portfolio for priority biological threats, some of the challenges in manufacturing viral vector vaccines, the need to strengthen live virus manufacturing capabilities, and future opportunities to capitalize on the use of viral vectors to improve the sustainability of the Biomedical Advanced Research and Development Authority’s vaccine portfolio.https://www.mdpi.com/2076-393X/13/1/73viral vectorsvaccine manufacturingvaccine manufacturing sustainabilityfilovirusesBARDABiomedical Advanced Research and Development Authority |
| spellingShingle | Lindsay A. Parish Shyam Rele Kimberly A. Hofmeyer Brooke B. Luck Daniel N. Wolfe Strategic and Technical Considerations in Manufacturing Viral Vector Vaccines for the Biomedical Advanced Research and Development Authority Threats Vaccines viral vectors vaccine manufacturing vaccine manufacturing sustainability filoviruses BARDA Biomedical Advanced Research and Development Authority |
| title | Strategic and Technical Considerations in Manufacturing Viral Vector Vaccines for the Biomedical Advanced Research and Development Authority Threats |
| title_full | Strategic and Technical Considerations in Manufacturing Viral Vector Vaccines for the Biomedical Advanced Research and Development Authority Threats |
| title_fullStr | Strategic and Technical Considerations in Manufacturing Viral Vector Vaccines for the Biomedical Advanced Research and Development Authority Threats |
| title_full_unstemmed | Strategic and Technical Considerations in Manufacturing Viral Vector Vaccines for the Biomedical Advanced Research and Development Authority Threats |
| title_short | Strategic and Technical Considerations in Manufacturing Viral Vector Vaccines for the Biomedical Advanced Research and Development Authority Threats |
| title_sort | strategic and technical considerations in manufacturing viral vector vaccines for the biomedical advanced research and development authority threats |
| topic | viral vectors vaccine manufacturing vaccine manufacturing sustainability filoviruses BARDA Biomedical Advanced Research and Development Authority |
| url | https://www.mdpi.com/2076-393X/13/1/73 |
| work_keys_str_mv | AT lindsayaparish strategicandtechnicalconsiderationsinmanufacturingviralvectorvaccinesforthebiomedicaladvancedresearchanddevelopmentauthoritythreats AT shyamrele strategicandtechnicalconsiderationsinmanufacturingviralvectorvaccinesforthebiomedicaladvancedresearchanddevelopmentauthoritythreats AT kimberlyahofmeyer strategicandtechnicalconsiderationsinmanufacturingviralvectorvaccinesforthebiomedicaladvancedresearchanddevelopmentauthoritythreats AT brookebluck strategicandtechnicalconsiderationsinmanufacturingviralvectorvaccinesforthebiomedicaladvancedresearchanddevelopmentauthoritythreats AT danielnwolfe strategicandtechnicalconsiderationsinmanufacturingviralvectorvaccinesforthebiomedicaladvancedresearchanddevelopmentauthoritythreats |